Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
Journal article published in 2024 by
Gilles Crochet,
Gloria Iacoboni 
,
Audrey Couturier ,
Emmanuel Bachy ,
Josu Iraola-Truchuelo ,
Thomas Gastinne,
Guillaume Cartron ,
Tom Fradon,
Bastien Lesne,
Mi Kwon ,
Romain Gounot,
Nuria Martínez-Cibrian,
Cristina Castilla-Llorente,
Pau Abrisqueta,
Manuel Guerreiro
and other authors.
,
Audrey Couturier ,
Emmanuel Bachy ,
Josu Iraola-Truchuelo ,
Thomas Gastinne,
Guillaume Cartron ,
Tom Fradon,
Bastien Lesne,
Mi Kwon ,
Romain Gounot,
Nuria Martínez-Cibrian,
Cristina Castilla-Llorente,
Pau Abrisqueta,
Manuel Guerreiro
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.